Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Deloitte
Chinese Patent Office
Medtronic
Daiichi Sankyo
Cipla
McKesson
McKinsey
Accenture

Generated: January 20, 2019

DrugPatentWatch Database Preview

Romiplostim - Biologic Drug Details

« Back to Dashboard

Summary for romiplostim
Tradenames:1
Patents:18
Applicants:1
BLAs:1
Suppliers: see list1
Pharmacology for romiplostim

US Patents for romiplostim

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source
Amgen NPLATE romiplostim INJECTABLE; SUBCUTANEOUS 125268 001 2008-08-22 ➤ Sign Up SIO2 MEDICAL PRODUCTS, INC. (Auburn, AL) ➤ Sign Up RX search
Amgen NPLATE romiplostim INJECTABLE; SUBCUTANEOUS 125268 001 2008-08-22 ➤ Sign Up University of the Sciences of Philadelphia (Philadelphia, PA) ➤ Sign Up RX search
Amgen NPLATE romiplostim INJECTABLE; SUBCUTANEOUS 125268 001 2008-08-22 ➤ Sign Up ➤ Sign Up RX search
Amgen NPLATE romiplostim INJECTABLE; SUBCUTANEOUS 125268 001 2008-08-22 ➤ Sign Up Amgen Inc. (Thousand Oaks, CA) ➤ Sign Up RX company
Amgen NPLATE romiplostim INJECTABLE; SUBCUTANEOUS 125268 001 2008-08-22 ➤ Sign Up Amgen Inc. (Thousand Oaks, CA) ➤ Sign Up RX company
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for romiplostim

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
6 Finland ➤ Sign Up
/2009 Austria ➤ Sign Up PRODUCT NAME: ROMIPLOSTIM; REGISTRATION NO/DATE: EU/1/08/497/001-002 20090204
2009 00025 Denmark ➤ Sign Up
1124961/01 Switzerland ➤ Sign Up FORMER REPRESENTATIVE: BOHEST AG, CH
C/GB09/035 United Kingdom ➤ Sign Up SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB09/035 GRANTED TO KIRIN-AMGEN INC. IN RESPECT OF THE PRODUCT ROMIPLOSTIM, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6361 DATED 20/04/2011 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 05/02/2024.
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Fish and Richardson
Queensland Health
UBS
Boehringer Ingelheim
Farmers Insurance
Argus Health
McKesson
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.